Allergy Diagnostics and Therapeutics Market to Reach $28.8 Billion by 2035

Allergy diagnostics and therapeutics market was valued at $16.8 billion in 2025 and is projected to reach $28.8 billion by 2035, growing at a CAGR of 5.5% during the forecast period (2026-2035). The increasing clinical burden of allergic conditions remains a primary factor supporting the expansion of the allergy diagnostics and therapeutics market. Recent data from the Centers for Disease Control and Prevention indicates that approximately 31.7% of adults in the United States were diagnosed with at least one allergic condition in 2024, reflecting a significant patient pool requiring ongoing diagnosis and treatment. Seasonal allergies alone affect nearly one-quarter of the adult population (25.2%), while food allergies and eczema account for 6.7% and 7.7%, respectively. Among children, the prevalence remains similarly high, with 29.5% diagnosed with allergic conditions, highlighting early onset and long-term disease management requirements.  This widespread prevalence is contributing to consistent demand for diagnostic assays, including immunoassays and allergen panels, across clinical settings. Healthcare systems are increasingly prioritizing early-stage detection to reduce disease severity and associated complications. Such trends are directly translating into higher testing volumes and repeat diagnostic utilization. The chronic and often progressive nature of allergic diseases further reinforces recurring demand for both diagnostics and therapeutic interventions.

Browse the full report description of “Allergy Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report by Offering (Diagnostics, Therapeutics), by Allergy Type (Food Allergy, Respiratory Allergy, Skin Allergy, Drug Allergy, and Others), by End User (Hospitals, Diagnostic Laboratories, and Others), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/allergy-diagnostics-and-therapeutics-market-size

Innovation Leaders Transforming the Allergy Diagnostics and Therapeutics Market

The key players in the allergy diagnostics and therapeutics market include Thermo Fisher Scientific, Danaher Corporation, Siemens Healthineers, Roche, Sanofi, among others.

• In March 2026, Novartis announced the acquisition of Excellergy for up to $2 billion, aimed at expanding its next-generation allergy treatment portfolio.

• In January 2026, GSK entered into a $2.2 billion agreement to acquire RAPT Therapeutics, strengthening its immunology and allergy pipeline.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Offering
  • By Allergy Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Thermo Fisher Scientific, Danaher Corporation, Siemens Healthineers, Roche, Sanofi, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Allergy Diagnostics and Therapeutics Market Report Segment

By Offering

• Diagnostics
• Therapeutics

By Allergy Type

• Food Allergy
• Respiratory Allergy
• Skin Allergy
• Drug Allergy
• Others

By End User

• Hospitals
• Diagnostic Laboratories
• Others

Global Allergy Diagnostics and Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/allergy-diagnostics-and-therapeutics-market-size